Fortis Healthcare Limited has informed the Exchange regarding Board meeting held on February 13, 2026.
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fortis Healthcare's board approved unaudited standalone and consolidated results for Q3 FY26 (quarter ended Dec 31, 2025) and 9M FY26. Standalone revenue from operations rose 20.7% YoY to ₹44,293 crore in Q3 and 25.9% YoY to ₹133,177 crore for 9M. Operating margin (EBITDA margin) expanded to 22.3% in Q3 from 18.2% a year ago, supported by revenue growth. Net profit for Q3 was ₹2,840 crore (down from ₹3,956 crore in Q3 FY25), while 9M profit jumped to ₹20,537 crore, aided by an exceptional gain of ₹4,319 crore (mainly reversal of impairment in subsidiary investments). The board also approved a new ESOP 2026 scheme covering 1.50 crore stock options, subject to shareholder approval, and a revision to the Related Party Transaction Policy. The auditor (BSR & Co. LLP) issued an unmodified limited review report, but highlighted ongoing SFIO investigation and the Supreme Court order related to the RHT Health Trust transactions as 'emphasis of matter' matters.
Strong revenue growth and margin expansion are positive signals for the business. However, headline profit growth in 9M is largely driven by one-time exceptional items (impairment reversals), while underlying profit before exceptional items was broadly flat YoY. Finance costs have more than doubled YoY, and the ESOP, if approved, will lead to future dilution. Ongoing legacy legal and regulatory matters remain overhangs, though auditors have not qualified the results.